M A Radtke1, C Lee-Seifert, S J Rustenbach, I Schäfer, M Augustin. 1. Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm), Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Deutschland.
Abstract
BACKGROUND: Products containing dexpanthenol are used to treat irritated and inflamed skin. So far there is a lack of data for the evidence of patient-relevant benefits. OBJECTIVE: Assessment of the patient-relevant benefit of ointments containing dexpanthenol in the self-medicated therapy of irritated skin. METHODS: Prospective, observational study in a network of 392 pharmacies. Consecutive recruitment of n=1,886 patients with symptoms of irritated skin, including non-inflammatory intervals of atopic eczema, other xerotic skin conditions and impairment of skin barrier. The patient-relevant benefit was ascertained prior to and 7-10 days after treatment through the patient-benefit index (PBI). RESULTS: The PBI showed that 91.5% of the patients experienced a relevant benefit from treatment. 94.7% directly indicated to have had achieved successful therapeutic results. All symptoms of irritated skin (e.g. xerosis, erythema, desquamation) significantly improved (p<or=0,001). The subjective response was independent of age, gender and underlying skin disease. CONCLUSION: High patient-relevant benefits were observed in the treatment of irritated skin with dexpanthenol ointment.
BACKGROUND: Products containing dexpanthenol are used to treat irritated and inflamed skin. So far there is a lack of data for the evidence of patient-relevant benefits. OBJECTIVE: Assessment of the patient-relevant benefit of ointments containing dexpanthenol in the self-medicated therapy of irritated skin. METHODS: Prospective, observational study in a network of 392 pharmacies. Consecutive recruitment of n=1,886 patients with symptoms of irritated skin, including non-inflammatory intervals of atopic eczema, other xerotic skin conditions and impairment of skin barrier. The patient-relevant benefit was ascertained prior to and 7-10 days after treatment through the patient-benefit index (PBI). RESULTS: The PBI showed that 91.5% of the patients experienced a relevant benefit from treatment. 94.7% directly indicated to have had achieved successful therapeutic results. All symptoms of irritated skin (e.g. xerosis, erythema, desquamation) significantly improved (p<or=0,001). The subjective response was independent of age, gender and underlying skin disease. CONCLUSION: High patient-relevant benefits were observed in the treatment of irritated skin with dexpanthenol ointment.
Authors: Wolfgang Greiner; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Jan Busschbach; Martin Buxton; Paul Dolan; Paul Kind; Paul Krabbe; Arto Ohinmaa; David Parkin; Montserat Roset; Harri Sintonen; Aki Tsuchiya; Frank de Charro Journal: Eur J Health Econ Date: 2003-09
Authors: Louis P Garrison; Peter J Neumann; Pennifer Erickson; Deborah Marshall; C Daniel Mullins Journal: Value Health Date: 2007 Sep-Oct Impact factor: 5.725